Loading
Evandro de Azambuja is a breast oncologist who studies heart safety of HER2-targeted therapy in BIG trials.
Evandro de Azambuja is Head of the Medical Support Team at Institut Jules Bordet in Brussels and a medical oncologist working with the Breast International Group (BIG). His specialisms are breast cancer, cardio-oncology and adjuvant HER2 therapy. He works on adjuvant HER2 trials and the cardiac safety of trastuzumab-based therapy. His papers include the NeoALTTO phase 3 trial of lapatinib with trastuzumab in HER2-positive early breast cancer and its link between pathological complete response and outcomes, the New England Journal of Medicine report of adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer, and an analysis of trastuzumab-associated cardiac events at long-term follow-up in the HERA trial. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response | The Lancet Oncology | 2014 |
| Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer | New England Journal of Medicine | 2017 |
| Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01) | Journal of Clinical Oncology | 2014 |
| OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer | New England Journal of Medicine | 2021 |
Shares Breast International Group (BIG), Institut Jules Bordet, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, HER2-positive breast cancer.
Shares Breast International Group (BIG), HER2-positive breast cancer.
Shares Breast International Group (BIG), HER2-positive breast cancer.
Shares Breast International Group (BIG), HER2-positive breast cancer.